- WKN: A2YPGM
- ISIN: DE000A2YPGM4
- Land: Deutschland
Nachricht vom 13.05.2019 | 19:13
curasan must cope with significant setbacks in international sales in 2018
DGAP-News: curasan AG / Key word(s): Annual Results
Thus, net sales decreased by 14.0 percent to 5.8 million Euros (2017: 6.8 Mio. Euro). Whereas in the domestic market Germany but also in Asia a slight growth could be experienced, the company had to cope with bitter losses in sales mainly in the second half of the year, especially in the foreign markets in Europe and the Middle East, as well as in the US, a market so important for economic success.
Accordingly, the extensive marketing and sales expenses had a negative impact on the company's earnings. Earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR -3.8 million were 73.0 percent lower than in the previous year.
The key financial figures on the development in the financial year 2018 are as follows:
"We did not succeed in reflecting the undisputed advantages of our products in an appropriate sales development. The deteriorating framework conditions then did the rest, especially in the second half of the year," explains Michael Schlenk, CEO of curasan AG. "When I took office as CEO almost five years ago, we had ambitious goals. And we have worked hard to realign the company, focus more strongly, reduce old liabilities and expand the sales base with new approvals and product developments. Therefore, it hurts me a lot personally that despite all our efforts we could not achieve economic success on our own.
Following the successful refinancing of the company in the second quarter of 2019, its continued existence is secured for the time being. The company will undertake extensive restructuring measures and communicate them to the market in a timely manner.
The development in the first 4 months of 2019 again shows a pleasing uptrend in many markets.
CEO Michael Schlenk will fulfil his contract defined for a period of 5 years, but is willing to cede his office to a successor still to be named before expiration of his management contract on October 1, 2019.
The company has positioned itself very well in marketing, regulatory affairs, medical affairs, production and research and development.
Discussions with potential internationally active strategic partners should still support to further expand the established sales structures and the grown customer base in order to also bring sales on the winning track. For the current financial year the company expects a stabilization of the net sales within a range of EUR 6.2 and 7.0 million. On EBITDA level a target value between EUR -3.2 and -2.8 million is expected.
The complete Annual Report 2018 is available for download on the company's website at the following link:
About curasan AG:
|Phone:||06027/40 900 0|
|Fax:||06027/40 900 29|
|Listed:||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||810671|
|End of News||DGAP News Service|
curasan AG: Aufhebung des Insolvenzverfahrens
curasan AG: Die in der Gläubigerversammlung an ...
curasan AG: Kapitalmaßnahmen im Rahmen des Erö ...
curasan AG: Erörterungs- und Abstimmungstermin ...
curasan AG: Abschlussprüfer erteilt Versagung ...
Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet
Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.
Der AKTIONÄR News
28. September 11:50 BioNTech, Moderna & Co: Deswegen ist die Hoffnung groß
28. September 11:38 BMW: Neue Elektromodelle = Comeback der Aktie?
28. September 10:55 Devisen: Türkische Lira stürzt wieder ab – Zinserhöhung verpufft
28. September 10:49 FuelCell Energy: Weitere Millionen vom U.S. Energieministerium – das ...
28. September 10:25 Der DAX im Rausch
Original-Research: Signature AG (von Sphene Capital GmbH): Buy
28. September 2020